Summary#
This bill creates a national public awareness campaign, run by the CDC, about detection, screening, and management of type 1 diabetes. It requires written materials, public service announcements, targeted and culturally appropriate resources, and grants to nonprofits and public health departments to increase screening. The bill authorizes $5,000,000 per year for fiscal years 2027–2031 and requires a report to Congress within one year.
- Main change: replaces an existing subsection to add a focused, evidence-based national campaign on type 1 diabetes awareness and screening.
- Grants: funds go to private nonprofits to run the campaign and to State, local, and Tribal public health departments to increase screening and share where to get screened.
- Targeting: resources must be culturally and linguistically tailored and aimed at communities with the largest recent increases in type 1 diabetes.
- Scope: campaign materials must reach health care providers, public health departments, elementary/secondary schools, and institutions of higher education.
- Reporting: HHS must submit a qualitative assessment of the campaign and its impact on detection, screening, and management within one year.
- What is unclear: the bill does not define which specific screening tests or age groups should be screened, nor does it require payment for screening or follow-up care.
What it means for you#
- General public / families: You may see more public service announcements and written materials about early signs of type 1 diabetes and where to get screening.
- Parents and students: Schools may receive materials or outreach about recognizing early symptoms and options for screening.
- People at risk or newly diagnosed: The campaign aims to point to medically appropriate resources and training for newly diagnosed people, which could mean more local information and referrals.
- Health care providers (primary care, pediatricians, community health centers): You may receive education materials and communication resources to help identify symptoms and refer for screening. The campaign could increase patient questions or requests for screening.
- State, local, and Tribal public health departments: These agencies can apply for grants to develop screening strategies and distribute information. They may take a larger role in local outreach.
- Nonprofit organizations: Groups with experience running public campaigns may receive federal grants to design and implement parts of the campaign.
- Taxpayers: The federal government has authorized spending to run and support the campaign (see Expenses); the bill does not itself require new taxes.
Expenses#
Estimated public cost: the bill authorizes $5,000,000 per year for fiscal years 2027–2031.
- Authorized appropriations: $5,000,000 annually for FY2027–2031, to remain available until spent.
- Likely additional costs: administrative expenses at HHS/CDC to run grant programs, staff time for outreach and evaluation, and costs to grant recipients for implementing campaigns and screening outreach.
- Screening and treatment costs: the bill does not fund routine screening tests or guarantee payment for screening or follow-up care; any costs for tests, lab services, or medical treatment would depend on existing health coverage and provider arrangements.
- Fiscal estimates: No public CBO score or additional fiscal note is included in the bill text or summary materials provided.
Proponents' View#
The bill appears intended to increase early detection of type 1 diabetes and improve links to care by educating the public and health care providers.
- It could reduce missed or late diagnoses by raising awareness of early symptoms and screening availability.
- Targeted, culturally and linguistically tailored materials may reach communities with rising incidence more effectively.
- Grants to public health departments and nonprofits could build local capacity to promote screening and share where to get screened.
- Coordination with schools and health providers may help spot cases earlier among children and young adults.
Opponents' View#
The bill’s text raises several practical questions and trade-offs that could limit its impact.
- Funding level: $5 million per year is relatively small for a national campaign, so reach and impact could be limited.
- No funding for screening tests or treatment: the bill promotes screening but does not pay for screening tests or guarantee coverage for follow-up care, which could limit real-world increases in screening.
- Unclear screening details: the bill does not specify which tests, age groups, or clinical guidelines should be used, leaving implementation decisions to agencies and grantees.
- Evaluation limits: the required report is a qualitative assessment; the bill does not require specific measurable targets or a detailed evaluation plan to judge impact on diagnosis rates or outcomes.
- Uneven access: reliance on grants and nonprofit partners may produce uneven coverage across regions, especially where local capacity is weak.